^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SNC103

i
Other names: SNC103, CAR-NK-CD19 cells, cord blood derived anti-CD19 CAR-engineered NK cells, anti-CD19 chimeric antigen receptor(CAR)-modified NK cells, F01
Associations
Company:
Shanghai Simnova Bio
Drug class:
CD19 inhibitor, NK cell stimulant
Related drugs:
Associations
3ms
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=55, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd. | Initiation date: Jan 2024 --> Apr 2024
Trial initiation date
|
cyclophosphamide • SNC103
4ms
New P1 trial
|
cyclophosphamide • fludarabine IV • SNC103
4ms
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=55, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd.
New P1 trial
|
cyclophosphamide • SNC103
over1year
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=2, Completed, Shanghai Simnova Biotechnology Co.,Ltd. | Recruiting --> Completed | N=21 --> 2 | Trial completion date: Jul 2024 --> Nov 2022 | Trial primary completion date: Jul 2023 --> Nov 2022
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • SNC103
over1year
New P1 trial
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • SNC103
3years
Clinical • New P1 trial
|
CD19 (CD19 Molecule)
|
fludarabine IV • SNC103